Wellington Management Group
FDMT icon

Wellington Management Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Wellington Management Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01M Sell
108,872
-21,380
-16% -$186K ﹤0.01% 1672
2025
Q4 		$977K Sell
130,252
-5,218
-4% -$52.9K ﹤0.01% 1720
2025
Q3 		$1.18M Buy
+135,470
New +$810K ﹤0.01% 1743
2025
Q2 		– Sell
-247,471
Closed -$799K – 1981
2025
Q1 		$799K Buy
247,471
+70,192
+40% +$331K ﹤0.01% 1753
2024
Q4 		$987K Buy
177,279
+11,089
+7% +$87K ﹤0.01% 1721
2024
Q3 		$1.8M Sell
166,190
-13,254
-7% -$220K ﹤0.01% 1567
2024
Q2 		$3.77M Buy
179,444
+9,796
+6% +$246K ﹤0.01% 1382
2024
Q1 		$5.4M Sell
169,648
-10,827
-6% -$276K ﹤0.01% 1308
2023
Q4 		$3.66M Buy
180,475
+7,753
+4% +$102K ﹤0.01% 1373
2023
Q3 		$2.2M Buy
172,722
+3,638
+2% +$60.8K ﹤0.01% 1456
2023
Q2 		$3.06M Sell
169,084
-6,432
-4% -$118K ﹤0.01% 1394
2023
Q1 		$3.02M Sell
175,516
-85,188
-33% -$1.66M ﹤0.01% 1402
2022
Q4 		$5.79M Sell
260,704
-5,188
-2% -$80.1K ﹤0.01% 1234
2022
Q3 		$2.14M Buy
265,892
+143,508
+117% +$1.3M ﹤0.01% 1515
2022
Q2 		$855K Hold
122,384
– – ﹤0.01% 1705
2022
Q1 		$1.85M Sell
122,384
-139,563
-53% -$2.19M ﹤0.01% 1624
2021
Q4 		$5.75M Buy
+261,947
New +$6.42M ﹤0.01% 1428
2021
Q2 		– Sell
-90,251
Closed -$3.91M – 2171
2021
Q1 		$3.91M Sell
90,251
-118,928
-57% -$5.27M ﹤0.01% 1479
2020
Q4 		$8.67M Buy
+209,179
New +$8.64M ﹤0.01% 1217

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group's FDMT Position: Q1 2026 in Review

Wellington Management Group reduced its 4D Molecular Therapeutics (FDMT) stake by 16% in Q1 2026, selling an estimated $186K and leaving 108,872 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1672.

Wellington Management Group first reported a position in FDMT in Q4 2020 and has held it in 19 quarters since. The position peaked at $8.67M in Q4 2020. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Wellington Management Group held 108,872 shares of 4D Molecular Therapeutics worth $1.01M as of Q1 2026.
  • Wellington Management Group sold 21,380 4D Molecular Therapeutics shares in Q1 2026, an estimated $186K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1672 holding.
  • Wellington Management Group first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 19 quarters since.
  • Wellington Management Group's 4D Molecular Therapeutics position peaked at $8.67M in Q4 2020.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.